Overall, TgF344-AD, the double transgenic rat model exhibits an age-dependent AD pathology, including amyloid-beta plaques, tau hyperphosphorylated, neuronal loss, neuroinflammation, and cognitive and behavioral deficits. This evidence concerns the gene MAPT and Alzheimer disease.